serabelisib
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 11, 2019 (NCT04073680)
Timeline
Indications
Mechanism of action
- PI3-kinase p110-beta subunitINHIBITOR
PIK3CB inhibitor
- PI3-kinase p110-alpha subunitINHIBITOR
PI3-kinase p110-alpha subunit inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc2cc(-c3ccc4ncc(C(=O)N5CCOCC5)n4c3)ccc2o1- Mol. weight
- 363.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3935857 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06463028 | Phase 2 | Dec 31, 2024 | Faeth Therapeutics, GOG Foundation, Inc. |
| NCT05300048 | Phase 1 | Apr 22, 2022 | Faeth Therapeutics, Memorial Sloan-Kettering Cancer Center |
| NCT04073680 | Phase 1/Phase 2 (Phase 2) | Nov 11, 2019 | Petra Pharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Faeth Therapeutics | For profit | 2 | 2 | 2 | 2022 |
| GOG Foundation, Inc. | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Petra Pharma | For profit | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1